Abstract
We wrote this letter to comment on the recently published guidelines on the use of ribavirin for respiratory syncytial virus (RSV) infection,1 and to commend the commentary provided by Drs Wald and Dashefsky questioning these recommendations.2 In addition we point out the recent advertising campaign by ICN Canada where it is claimed that the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) studies3,4 show "widespread underutilization" of ribavirin for RSV bronchiolitis,5 a conclusion not supported by detailed review of the literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
